Warfarin administration disrupts the assembly of mineralized nodules in the osteoid

Journal of Electron Microscopy

Volumn 58, Issue 2, 2009, Pages 55-65

  Amizuka, Norio ^a   Li, Minqi ^a   Hara, Kuniko ^b   Kobayashi, Masatoshi ^b   De Freitas, Paulo H L ^a   Ubaidus, Sobhan ^a   Oda, Kimimitsu ^a,c   Akiyama, Yasuhiro ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Immunoelectron microscopy; Mineralization; Mineralized nodule; Osteoblast; Osteocalcin; Warfarin

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ISOENZYME; OSTEOCALCIN; TARTRATE-RESISTANT ACID PHOSPHATASE; WARFARIN;

ANIMAL; ARTICLE; BONE MINERALIZATION; CYTOCHEMISTRY; DRUG EFFECT; FEMUR; FISCHER 344 RAT; IMMUNOELECTRON MICROSCOPY; MALE; METABOLISM; RAT; TIBIA; ULTRASTRUCTURE;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; CALCIFICATION, PHYSIOLOGIC; FEMUR; HISTOCYTOCHEMISTRY; ISOENZYMES; MALE; MICROSCOPY, IMMUNOELECTRON; OSTEOCALCIN; RATS; RATS, INBRED F344; TIBIA; WARFARIN;

RATTUS;

BONE; CRYSTALLINE MATERIALS; DRUG PRODUCTS; OSTEOBLASTS; PHOSPHATASES;

BONE MINERALIZATION; CONTROL GROUPS; CRYSTALLINE PARTICLES; DISTILLED WATER; IMMUNOELECTRON MICROSCOPY; MINERALISATION; MINERALIZED NODULES; OSTEOCALCIN; WARFARIN; WATER CONTROL;

MINERALOGY;

EID: 62549148143     PISSN: 00220744     EISSN: 14779986     Source Type: Journal    
DOI: 10.1093/jmicro/dfp008     Document Type: Article

References (55)

1. Hauschika P V, Lian J B, and Gallop P M (1975) Direct identification of the calcium-binding amino acids, γ-carboxyglutamate, in mineralized tissue. Proc. Natl Acad. Sci. USA 72: 3925-3929.
2. Price P A, Otsuka A S, Poser J W, Kristaponis J, and Raman N (1976) Characterization of a γ-carboxyglutamic acid containing protein from bone. Proc. Natl Acad. Sci. USA 73: 1447-1451.
3. Price P A, and Nishimoto S K (1980) Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc. Natl Acad. Sci. USA 77: 2234-2238.
4. Hauschka P V and Carr S A (1982) Calcium-dependent alpha-helical structure in osteocalcin. Biochemistry 21: 2538-2547.
5. Price P A, and Williamson M K (1985) Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J. Biol. Chem. 260: 14971-14975.
6. Cairns J R, and Price P A (1994) Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely γ-carboxylated in humans. J. Bone Miner. Res. 9: 1989-1997.
7. Suttie J W (1984) Vitamin K. In: Machlin L J (ed.), Handbook of Vitamins, pp 147-198 (Dekker, New York).
8. Lian J B, and Gundberg C M (1988) Osteocalcin. Biochemical consideration and clinical applications. Clin. Orthop. 226: 267-291.
9. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, and Karsenty G (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382(6590): 448-452.
10. Pastoureau P, Vergnaud P, Meunier P J, and Delmas P D (1993) Osteopenia and bone-remodeling abnormalities in warfarin-treated lambs. J. Bone Miner. Res. 8: 1417-1426.
11. Simon R R, Beaudin S M, Johnston M, Walton K J, and Shaughnessy S G (2002) Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb. Res. 105: 353-358.
12. Price P A, Williamson M K, Haba T, Dell R B and Jee W S (1982) Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc. Natl Acad. Sci. USA 79(24): 7734-7738.
13. Price P A, and Sloper S A (1983) Concurrent warfarin treatment further reduced bone mineral levels in 1,25-dihydroxyvitamin D3-treated rats. J. Biol. Chem. 258: 6004-6007.
14. Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, and Binkley N (2000) Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J. Bone Miner. Res. 15(5): 872-878.
15. Price P A, and Willamson M K (1981) Effects of warfarin on bone. Studies on vitamin K-dependent protein of rat bone. J. Biol. Chem. 256: 12754-12759.
16. Hirsh J (1991) Oral anticoagulant drugs. N. Engl. J. Med. 324: 1865-1875.
17. Levine M N, Raskob G, and Hirsh J (1989) Hemorrhagic complications of long-term anticoagulant therapy. Chest 95: 26S-36S.
18. Landefeld C S, and Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of out patient therapy. Am. J. Med. 87: 144-152.
19. Hall J G, Pauli R M, and Wilson K M (1980) Maternal and fetal sequelae of anti-coagulation during pregnancy. Am. J. Med. 68: 122-140.
20. Pauli R M, Lian J B, Mosher D F, and Suttie J W (1987) Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: cues to the mechanism of teratogenicity of coumarin derivatives. Am. J. Hum. Genet. 41: 566-583.
21. Fiore C E, Tamburino C, Foti R, and Grimaldi D (1990) Reduced axial bone mineral content in patients taking an oral anticoagulant. S. Med. J. 83(5): 538-542.
22. Resch H, Pietschmann P, Krexner E, and Willvonseder R (1991) Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. Eur. Heart J. 12(3): 439-441.
23. Monreal M, Olive A, Lafoz E, and del Rio L (1991) Heparins, coumarin, and bone density. Lancet 338(8768): 706.
24. Philip W J, Martin J C, Richardson J M, Reid D M, Webster J, and Douglas A S (1995) Decreased axial and peripheral bone density in patients taking long-term warfarin. Q JM 88(9): 635-640.
25. Sato Y, Honda Y, Kunoh H, and Oizumi K (1997) Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 28(12): 2390-2394.
26. Caraballo P J, Heit J A, Atkinson E J, Silverstein M D, O'Fallon W M, Castro M R, and Melton L J 3rd (1999) Long-term use of oral anticoagulants and the risk of fracture. Arch. Intern. Med. 159(15): 1750-1756.
27. Piro L D, Whyte M P, Murphy W A, and Birge S J (1982) Normal cortical bone mass in patients after long term coumadin therapy. J. Clin. Endocrinol. Metab. 54(2): 470-473.
28. Houvenagel E, Leloire O, Vanderlinden T, Graux P, Dutoit A, Tison F, Forzy G, Racadot A, and Vincent G (1989) The level of osteocalcin and bone mass in patients receiving anti-vitamin K agents. Rev. Rhum. Mal. Osteoartic. 56(10): 677-679.
29. Rosen H N, Maitland L A, Suttie J W, Manning W J, Glynn R J, and Greenspan S L (1993) Vitamin K and maintenance of skeletal integrity in adults. Am. J. Med. 94(1): 62-68.
30. Jamal S A, Browner W S, Bauer D C, and Cummings S R (1998) Warfarin use and risk for osteoporosis in elderly women. Study of osteoporotic fractures research group. Ann. Intern. Med. 128(10): 829-832.
31. Anderson H C, Cecil R, and Sajdera S W (1975) Calcification of rachitic rat cartilage in vitro by extracellular matrix vesicles. Am. J. Pathol. 79: 237-254.
32. Anderson H C (1995) Molecular biology of matrix vesicles. Clin. Orthop. 314: 266-280.
33. Anderson H C (2003) Matrix vesicles and calcification. Curr. Rheumatol. Rep. 5: 222-226.
34. Hoshi K, Ejiri S, and Ozawa H (2001) Localizational alterations of calcium, phosphorus, and calcification-related organics such as proteoglycans and alkaline phosphatase during bone calcification. J. Bone Miner. Res. 16: 289-298.
35. Ozawa H, Hoshi K, and Amizuka N (2008) Current concepts of bone biomineralization. J. Oral Sci. 50(1): 1-14.
36. Hoang Q Q, Sicheri F, Howard A J, and Yang D S (2003) Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 425: 977-980.
37. Hara K, Kobayashi M, and Akiyama Y (2005) Comparison of inhibitory effects of warfarin on gamma-carboxylation between bone and liver in rats. J. Bone Miner. Metab. 23(5): 366-372.
38. Amizuka N, Warshawsky H, Henderson J E, Goltzman D, and Karaplis A C (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126(6): 1611-1623.
39. Oda K, Amaya Y, Fukushi-Irie M, Kinameri Y, Ohsuye K, Kubota I, Fujimura S, and Kobayashi J (1999) A general method for rapid purification of soluble versions of glycosylphosphatidylinositol-anchored proteins expressed in insect cells: an application for human tissue-nonspecific alkaline phosphatase. J. Biochem. 126: 694-699.
40. Amizuka N, Kwan M Y, Goltzman D, Ozawa H, and White J H (1999) Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. J. Clin. Invest. 103: 373-381.
41. Asawa Y, Amizuka N, Hara K, Kobayashi M, Aita M, Li M, Kenmotsu S, Oda K, Akiyama Y, and Ozawa H (2004) Histochemical evaluation for the biological effect of menatetrenone on metaphyseal trabeculae of ovariectomized rats. Bone 35: 870-880.
42. Asawa Y, Aoki K, Ohya K, Ohshima H, and Takano Y (2004) Appearance of electron-dense segments: indication of possible conformational changes of pre-mineralizing collagen fibrils in the osteoid of rat bones. J. Electron Microsc. 53: 423-433.
43. Takano Y, Sakai H, Baba O, and Terashima T (2000) Differential involvement of matrix vesicles during the initial and appositional mineralization processes in bone, dentin, and cementum. Bone 26: 333-339.
44. Nakano T, Kaibara K, Tabata Y, Nagata N, Enomoto S, Marukawa E, and Umakoshi Y (2002) Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31: 479-487.
45. Hoshi K, Ejiri S, and Ozawa H (2001) Organic components of crystal sheaths in bones. J. Electron Microsc. 50: 33-40.
46. Bonucci E (2002) Crystal ghosts and biological mineralization: fancy spectres in an old castle, or neglected structures worthy of belief. J. Bone Miner. Metab. 20: 249-265.
47. Hunter G K, Hauschka P V, Poole A R, Rosenberg L C, and Goldberg H A (1996) Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem. J. 317: 59-64.
48. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795.
49. Prigodich R V, and Vesely M R (1997) Characterization of the complex between bovine osteocalcin and type I collagen. Arch. Biochem. Biophys. 345(2): 339-341.
50. Hellmich C h, and Ulm F J (2002) Are mineralized tissues open crystal foams reinforced by crosslinked collagen? Some energy arguments. J. Biomech. 35(9): 1199-1212.
51. Pauli R M (1988) Mechanism of bone and cartilage maldevelopment in the warfarin embryopathy. Pathol. Immunopathol. Res. 7(1-2): 107-112.
52. de Vries T W, Van Der Veer E, and Heijmans H S (1993) Warfarin embryopathy: patient, possibility, pathogenesis and prognosis. Br. J. Obstet. Gynaecol. 100(9): 869-871.
53. Feteih R, Tassinari M S, and Lian J B (1990) Effect of sodium warfarin on vitamin K-dependent proteins and skeletal development in the rat fetus. J. Bone Miner. Res. 5(8): 885-894.
54. Luo G, Ducy P, McKee M D, Pinero G J, Loyer E, Behringer R R, and Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620): 78-81.
55. Yagami K, Suh J Y, Enomoto-Iwamoto M, Koyama E, Abrams W R, Shapiro I M, Pacifici M, and Iwamoto M (1999) Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J. Cell Biol. 147(5): 1097-1108.